Chinese Expert Consensus on 131I therapy for Graves’ hyperthyroidism in children and adolescents

Title: Chinese Expert Consensus on 131I therapy for Graves’ hyperthyroidism in children and adolescents
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: This consensus will be helpful for practitioners, nurses, technicians and relevant scientific research workers engaged in hyperthyroidism related work.
Evidence classification method: We will assess the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system and classify evidence as to be high, moderate, low, or very low certainty.The initial evaluation of RCT was high-quality evidence, and the initial evaluation of observational study was low-quality evidence. In the process of evidence grading, five factors such as limitation, imprecision, inconsistency, indirectness and publication bias were downgraded, while three factors such as large amount of effect, dose response relationship and possible confounding factors were upgraded.
Development unit: Shanghai Thyroid Disease Research Center; The tenth People's Hospital affiliated to Tongji University
Registration time: 2022-09-21
Registration number: PREPARE-2022CN613
Purpose of the guideline: 131I therapy, as a routine treatment for hyperthyroidism, has been widely used in children and adolescents with Graves′ hyperthyroidism(GH). However, due to the particularity of children and adolescents, most experts at home and abroad are relatively cautious about using 131I to treat children and adolescents with GH due to their concerns about secondary malignant tumors after 131I therapy. In view of the continuous emergence of new evidence on 131I treatment of GH for children and adolescents, it is urgent to adopt evidence-based medicine to build a clinical diagnosis and treatment guide or expert consensus on 131I treatment of GH for children and adolescents under the cultural background of China, so as to guide and standardize the clinical diagnosis and treatment decisions on 131I treatment of GH for children and adolescents in China, and to protect the health of children and adolescents with GH.